Article

OBJECTIVE: To explore the dose equivalence ratio and treatment costs for abobotulinumtoxinA and incobotulinumtoxinA for patients with focal dystonias.
DESIGN: Patient chart review.
Adult patients with
blepharospasm (n = 19), cervical dystonia (n = 122), hemifacial spasm (n = 91) or
segmental/generalized dystonia (n = 19) at a neurology outpatient clinic.
METHODS: Patients were switched from established abobotulinumtoxinA therapy to
incobotulinumtoxinA at a ~4:1 unit ratio. Dose requirements, injection intervals,
treatment efficacy, and adverse events were evaluated for a period of >/= 1 year.
RESULTS: Patients were switched from abobotulinumtoxinA to incobotulinumtoxinA
with a mean dose ratio of 4.07 (standard deviation (SD) 0.50). After switching,
incobotulinumtoxinA dose requirements remained stable; the mean (SD) dose ratio
at the end of the review period (52-219 weeks after switching) was 3.89 (SD
0.58). Injection intervals also remained stable after switching. Adverse events
were injection site pain (n = 45) and bruising (n = 4). Five patients (2.0%)
discontinued incobotulinumtoxinA treatment: 4 stopped receiving injections, and 1
reverted to abobotulinumtoxinA. Switching to incobotulinumtoxinA reduced the mean
toxin expenditure to 76.7% of the cost of abobotulinumtoxinA. CONCLUSION: For
patients with conditions commonly treated in dystonia clinics, switching from
abobotulinumtoxinA to incobotulinumtoxinA, given at equivalent doses (~4:1 unit
ratio) at similar intervals, was effective, well tolerated and achieved cost
savings.

Langue : ANGLAIS